Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, is pursuing a new indication in inflammatory disorders, a field which the Company has specialized in over the past few years. The Company will also develop its CF101 drug for the treatment of psoriasis skin disorder. This adds to the other indications currently in different phases of clinical trials, including rheumatoid arthritis (RA) and dry eye syndrome. Once this phase II clinical trial is initiated, Can-Fite will have 3 applications for CF101 in its development pipeline.
